Biogen, Eisai Get January 2025 FDA Action Date for Monthly Leqembi

Seeking AlphaJun 11 00:09

FDA Suggests Safety Warning for Eli Lilly Alzheimer's Drug

Seeking AlphaJun 6 22:09

Biogen Favored at RBC as Eli Lilly Awaits FDA AdCom on Alzheimer's Drug

Seeking AlphaJun 6 01:10

Eisai Projects Major Growth for Alzheimer's Therapy Leqembi

Seeking AlphaMay 16 00:52

Biogen Partner Eisai Begins FDA Submissions for Injectable Alzheimer's Therapy

Seeking AlphaMay 15 19:44

Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI (Lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status

Eisai Co., Ltd. announced today that Eisai has initiated the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (U.S. brand name: LEQEMBI) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA.

PR NewswireMay 15 07:30